2002
DOI: 10.1097/00007890-200206150-00019
|View full text |Cite
|
Sign up to set email alerts
|

Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production1

Abstract: Inhibition of IL-10 production is a critical factor in the ability of tacrolimus to reverse ongoing allograft rejection.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
27
2
2

Year Published

2003
2003
2020
2020

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 54 publications
(36 citation statements)
references
References 32 publications
4
27
2
2
Order By: Relevance
“…Together these data suggest a tempo- (3,16). These data strongly point out the macrophage as the primary cell responsible for graft destruction, and rary functional deficit probably caused by loss of damaged graft tissue or due to the rapid weight gain of the support earlier observations that CsA can act directly on macrophages (8,15). growing recipients and confirms the regenerative capacity of adult porcine islets (26).…”
Section: Immunosuppression Recipient Ratssupporting
confidence: 87%
“…Together these data suggest a tempo- (3,16). These data strongly point out the macrophage as the primary cell responsible for graft destruction, and rary functional deficit probably caused by loss of damaged graft tissue or due to the rapid weight gain of the support earlier observations that CsA can act directly on macrophages (8,15). growing recipients and confirms the regenerative capacity of adult porcine islets (26).…”
Section: Immunosuppression Recipient Ratssupporting
confidence: 87%
“…The inability of cyclosporin A to overcome ongoing allograft rejection could be addressed by cotreating recipients with neutralizing anti-IL-10 antibody. These data suggest that intragraft IL-10 production might be a critical factor in persistent rejection resulting in chronic graft injury (Jiang et al, 2002).…”
Section: Invited Review Of Il-10 Therapymentioning
confidence: 88%
“…Also, there have been some studies of the influence of CSA on B cells and the humoral response (92)(93)(94). CSA did not suppress Ab production in autoimmune diseases and transplantations (95)(96)(97), suggesting that the target mechanism in T cells is different from that in B cells; CSA targets calcium activation in T cells but may not affect that pathway in B cells (93,(98)(99)(100). However, we speculate that the mechanism by which CSA enhanced Ab production here may be indirect and via induction of Treg cells.…”
Section: Discussionmentioning
confidence: 99%
“…Help for B cells might be a consequence of IL-10 production by induced Treg cells. Although IL-10 is considered to be an anti-inflammatory cytokine, its enhancement of B cell activation and Ab production has been known for decades (97,(107)(108)(109)(110). Induced Treg cells produce high levels of IL-10, and this has been suggested to lead to B cell maturation (108,111,112).…”
Section: Discussionmentioning
confidence: 99%